Health Care [ 5/12 ] | Pharmaceuticals [ 17/75 ]
NASDAQ | Common Stock
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity.
The company has an agreement with Asarina Pharma AB and Trigone.
Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 24, 26 | -0.29 Increased by +53.05% | -0.17 Decreased by -66.82% |
| Nov 13, 25 | -0.30 Increased by +58.33% | -0.45 Increased by +33.33% |
| Aug 7, 25 | -0.30 Increased by +49.15% | -0.40 Increased by +25.00% |
| May 23, 25 | -0.58 Increased by +19.44% | -0.31 Decreased by -87.10% |
| Mar 17, 25 | -0.62 Increased by +26.19% | -0.70 Increased by +11.43% |
| Nov 6, 24 | -0.72 Increased by +1.37% | -0.64 Decreased by -12.50% |
| Aug 7, 24 | -0.59 Increased by +29.76% | -0.83 Increased by +28.92% |
| May 8, 24 | -0.72 Increased by +17.24% | -0.85 Increased by +15.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by N/A% | -19.87 M Decreased by -6.49% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -10.09 M Increased by +53.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -9.87 M Increased by +44.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -17.56 M Increased by +19.56% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -18.66 M Increased by +25.86% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -21.73 M Increased by +1.25% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -17.77 M Increased by +29.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -21.83 M Increased by +17.07% | Decreased by N/A% Decreased by N/A% |